- IDEAYA Biosciences Inc IDYA announced further interim results from its Phase 2 clinical trial evaluating darovasertib and crizotinib combination in metastatic uveal melanoma (MUM) type of eye cancer.
- Confirmed overall response rate (ORR) of 45%, disease control rate (DCR) of 90%, and median progression-free survival (PFS) of ~7 months in 20 evaluable First-Line MUM patients.
- In the sixty-three (63) evaluable any-line MUM patients at the expansion dose, a confirmed overall response rate (ORR) of 30%, disease control rate (DCR) of 87%, and median PFS of ~7 months was observed.
- Twenty (20) evaluable hepatic-only MUM patients, including first-line and pre-treated patients with only hepatic metastases, confirmed ORR of 35%, DCR of 100%, and median PFS of ~11 months.
- IDEAYA plans to initiate a potential registration-enabling Phase 2/3 clinical trial in Q2 2023 in first-line HLA-A2 negative MUM patients.
- The company observed further evidence of clinical activity for darovasertib as neoadjuvant therapy in primary uveal melanoma (UM), including responses in primary ocular tumor lesions.
- Ocular tumor shrinkage in 9 of 9 (100%) UM / MUM patients, including a neoadjuvant UM patient with a partial response at 1 month and a second neoadjuvant UM patient who was spared enucleation with ~80% tumor shrinkage at four months.
- IDEAYA is initiating a company-sponsored clinical trial to evaluate darovasertib as monotherapy in (neo)adjuvant uveal melanoma and is evaluating potential near-term clinical neoadjuvant endpoints such as organ preservation (avoiding enucleation) for large ocular tumors and reduction in radiation dose and/or vision preservation for small or medium ocular tumors.
- Price Action: IDYA shares are up 27.30% at $19.01 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
